Snejana Hyllén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Snejana Hyllén has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Lindstedt
Department of Clinical Sciences, Lund University, Lund, Sweden
10 shared publications - Franziska Olm
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
8 shared publications Dag Edström
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
5 shared publications- Gabriel Hirdman
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
5 shared publications Margareta Mittendorfer
Department of Clinical Sciences, Lund University, Lund, Sweden
5 shared publications- Anna Niroomand
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
4 shared publications
Latest Publications
- Open Access
Cell therapy for regeneration of injured donor lungs for transplantation
Donor organ shortage remains the major barrier to transplantation resulting in deaths on the waiting list. For lungs, aspiration-related injury is a common cause of donor organ discard and increases the risk of primary graft dysfunction. Currently, no effective therapies exist to repair damaged donor lungs prior to transplantation. Here, we investigated whether mesenchymal stromal cells (MSCs) from bone marrow or full-term amniotic fluid could restore severely injured donor lungs in a porcine model integrating ex vivo lung perfusion, transplantation and post-transplant follow-up (n=48; 24 donors, 24 recipients). MSCs were administered either once during ex vivo lung perfusion or repeatedly across lung perfusion and the early post-transplant period and compared with placebo treated controls. A single dose conferred only partial benefit, whereas repeated dosing restored graft function, normalized gas exchange and haemodynamics, and prevented graft dysfunction. MSCs from both sources were similarly effective in repeated regimens. These findings identify dosing schedule, rather than cell source, as key determinant of durable organ rescue and support perfusion-guided cell therapy as potentially generalizable regenerative strategy across solid-organ transplantation.
Open AccessCell therapy for regeneration of injured donor lungs for transplantation
Donor organ shortage remains the major barrier to transplantation resulting in deaths on the waiting list. For lungs, aspiration-related injury is a common cause of donor organ discard and increases the risk of primary graft dysfunction. Currently, no effective therapies exist to repair damaged donor lungs prior to transplantation. Here, we investigated whether mesenchymal stromal cells (MSCs) from bone marrow or full-term amniotic fluid could restore severely injured donor lungs in a porcine model integrating ex vivo lung perfusion, transplantation and post-transplant follow-up (n=48; 24 donors, 24 recipients). MSCs were administered either once during ex vivo lung perfusion or repeatedly across lung perfusion and the early post-transplant period and compared with placebo treated controls. A single dose conferred only partial benefit, whereas repeated dosing restored graft function, normalized gas exchange and haemodynamics, and prevented graft dysfunction. MSCs from both sources were similarly effective in repeated regimens. These findings identify dosing schedule, rather than cell source, as key determinant of durable organ rescue and support perfusion-guided cell therapy as potentially generalizable regenerative strategy across solid-organ transplantation.
- Open Access
- 14 November 2025
- Published by Springer Nature in Research Square
Mitochondrial Therapy During Machine Perfusion Restores the Function of DCD Livers: A Cross-Circulation Evaluation for Transplant Suitability
Donation after circulatory death (DCD) has significantly increased the number of organs potentially available for transplantation. Livers are more vulnerable than most other solid organs to warm ischemia in the DCD process. The injury induced by warm ischemic time (WIT) is further exacerbated during cold ischemia and reperfusion, resulting in tissue damage caused by the production of reactive oxygen species. These are not only cytotoxic but also perpetuate mitochondrial dysfunction and cell death. To improve the utilization of livers from uncontrolled DCD (uDCD) or controlled DCD (cDCD) donors with prolonged WIT, new strategies to mitigate WIT must be developed.Ex vivo normothermic machine perfusion (NMP) has increased DCD organ utilization and improved the assessment of the viability of organs before transplantation. NMP could also serve as a platform for isolated treatment of organs prior to transplant. An innovative approach to mitigate organ injury is to treat damaged livers with mitochondrial transplantation (MTx). In this study, we tested the efficacy of xenogeneic mitochondrial administration to restore the function of porcine DCD livers with two hours of warm ischemia. DCD livers were explanted and connected to NMP, where mitochondrial transplantation was administered as a bolus dose in the portal vein and hepatic artery at the start of perfusion. After four hours of NMP, treated livers demonstrated a significant increase in bile production, improved bile quality, and restored cytoarchitecture.To further assess the transplantation suitability of these livers post-NMP, they were connected to cross-circulation (CC) with a recipient pig. After six hours of CC, untreated livers became oedematous, exhibited significant aspartate aminotransferase elevations in the bile, and showed cellular degeneration, including near-complete loss of Kupffer cells. In contrast, livers treated with MTx maintained function across CC and were comparable to healthy controls. These data validate the efficacy of MTx in restoring function in DCD livers exposed to prolonged ischaemic times, presenting a promising approach to expand the donor pool.
- 14 November 2025
- Published by Springer Nature in Research Square
Open AccessMitochondrial Therapy During Machine Perfusion Restores the Function of DCD Livers: A Cross-Circulation Evaluation for Transplant Suitability
Donation after circulatory death (DCD) has significantly increased the number of organs potentially available for transplantation. Livers are more vulnerable than most other solid organs to warm ischemia in the DCD process. The injury induced by warm ischemic time (WIT) is further exacerbated during cold ischemia and reperfusion, resulting in tissue damage caused by the production of reactive oxygen species. These are not only cytotoxic but also perpetuate mitochondrial dysfunction and cell death. To improve the utilization of livers from uncontrolled DCD (uDCD) or controlled DCD (cDCD) donors with prolonged WIT, new strategies to mitigate WIT must be developed.Ex vivo normothermic machine perfusion (NMP) has increased DCD organ utilization and improved the assessment of the viability of organs before transplantation. NMP could also serve as a platform for isolated treatment of organs prior to transplant. An innovative approach to mitigate organ injury is to treat damaged livers with mitochondrial transplantation (MTx). In this study, we tested the efficacy of xenogeneic mitochondrial administration to restore the function of porcine DCD livers with two hours of warm ischemia. DCD livers were explanted and connected to NMP, where mitochondrial transplantation was administered as a bolus dose in the portal vein and hepatic artery at the start of perfusion. After four hours of NMP, treated livers demonstrated a significant increase in bile production, improved bile quality, and restored cytoarchitecture.To further assess the transplantation suitability of these livers post-NMP, they were connected to cross-circulation (CC) with a recipient pig. After six hours of CC, untreated livers became oedematous, exhibited significant aspartate aminotransferase elevations in the bile, and showed cellular degeneration, including near-complete loss of Kupffer cells. In contrast, livers treated with MTx maintained function across CC and were comparable to healthy controls. These data validate the efficacy of MTx in restoring function in DCD livers exposed to prolonged ischaemic times, presenting a promising approach to expand the donor pool.
- 24 May 2025
- Published by SAGE Publications in Perfusion
- Vol. 41 (2) , 155-164
No benefit of adding mannitol to cardiopulmonary bypass priming solution assessing cystatin C. A randomized clinical trial
Introduction: There is no recommendation regarding the optimal prime solution for the cardiopulmonary bypass circuit in adult cardiac surgery. Despite the lack of scientific evidence, mannitol has frequently been added to the prime solution with intention to prevent acute kidney injury. The aim of this study was to investigate the impact of mannitol in cardiopulmonary bypass circuit prime in patients with preoperative renal dysfunction. Methods: This prospective, randomized, double-blind study included 70 patients, who underwent coronary artery bypass grafting. One group received 1200 mL of a prime based on Ringer’s acetate ( n = 35), and the other a prime consisting of 1000 mL Ringer’s acetate and 200 mL mannitol ( n = 35). Primary endpoint were levels of Cystatin C, a renal function biomarker. Changes in renal-related parameters, electrolytes, osmolality and acid-base status were monitored. Results: The median cystatin C on day four in the mannitol group were 1.6 mg/L (IQR 1.4-2.0 mg/L) and 1,8 mg/L (IQR 1.5-2.1 mg/L) in the Ringer’s acetate group at the same time. Using mixed model analysis, no differences in cystatin C ( p = 0.442), creatinine ( p = 0.203), estimated glomerular filtration rate ( p = 0.264) and urea ( p = 0.141) could be detected between the groups. The mannitol group showed a more pronounced reduction in sodium levels after cardiopulmonary bypass circuit commencement compared to the Ringer’s acetate group p < 0.001. Conclusions: In patients with preoperative renal dysfunction, the addition of mannitol in the prime solution did not show any renoprotective effect measured by cystatin C compared to a cardiopulmonary bypass circuit prime based on Ringer's acetate. This study was reported to ClinicalTrials.org, id: NCT03302286. Effects of Extra Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome Following Cardiac Surgery https://clinicaltrials.gov/study/NCT03302286?id=NCT03302286&rank=1
- 24 May 2025
- Published by SAGE Publications in Perfusion
- Vol. 41 (2) , 155-164
No benefit of adding mannitol to cardiopulmonary bypass priming solution assessing cystatin C. A randomized clinical trial
Introduction: There is no recommendation regarding the optimal prime solution for the cardiopulmonary bypass circuit in adult cardiac surgery. Despite the lack of scientific evidence, mannitol has frequently been added to the prime solution with intention to prevent acute kidney injury. The aim of this study was to investigate the impact of mannitol in cardiopulmonary bypass circuit prime in patients with preoperative renal dysfunction. Methods: This prospective, randomized, double-blind study included 70 patients, who underwent coronary artery bypass grafting. One group received 1200 mL of a prime based on Ringer’s acetate ( n = 35), and the other a prime consisting of 1000 mL Ringer’s acetate and 200 mL mannitol ( n = 35). Primary endpoint were levels of Cystatin C, a renal function biomarker. Changes in renal-related parameters, electrolytes, osmolality and acid-base status were monitored. Results: The median cystatin C on day four in the mannitol group were 1.6 mg/L (IQR 1.4-2.0 mg/L) and 1,8 mg/L (IQR 1.5-2.1 mg/L) in the Ringer’s acetate group at the same time. Using mixed model analysis, no differences in cystatin C ( p = 0.442), creatinine ( p = 0.203), estimated glomerular filtration rate ( p = 0.264) and urea ( p = 0.141) could be detected between the groups. The mannitol group showed a more pronounced reduction in sodium levels after cardiopulmonary bypass circuit commencement compared to the Ringer’s acetate group p < 0.001. Conclusions: In patients with preoperative renal dysfunction, the addition of mannitol in the prime solution did not show any renoprotective effect measured by cystatin C compared to a cardiopulmonary bypass circuit prime based on Ringer's acetate. This study was reported to ClinicalTrials.org, id: NCT03302286. Effects of Extra Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome Following Cardiac Surgery https://clinicaltrials.gov/study/NCT03302286?id=NCT03302286&rank=1
- Open Access
- 13 December 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12, e52553
Design and Rationale of Cytokine Filtration in Lung Transplantation (GLUSorb): Protocol for a Multicenter Clinical Randomized Controlled Trial
Background: Lung transplantation (LTx) is the only treatment option for end-stage lung disease. Despite improvements, primary graft dysfunction (PGD) remains the leading cause of early mortality and precipitates chronic lung allograft dysfunction, the main factor in late mortality after LTx. PGD develops within the first 72 hours and impairs the oxygenation capacity of the lung, measured as partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2). Increasing the PaO2/FiO2 ratio is thus critical and has an impact on survival. There is a general lack of effective treatments for PGD. When a transplanted lung is not accepted by the immune system in the recipient, a systemic inflammatory response starts where cytokines play a critical role in initiating, amplifying, and maintaining the inflammation leading to PGD. Cytokine filtration can remove these cytokines from the circulation, thus reducing inflammation. In a proof-of-concept preclinical porcine model of LTx, cytokine filtration improved oxygenation and decreased PGD. In a feasibility study, we successfully treated patients undergoing LTx with cytokine filtration (ClinicalTrials.gov; NCT05242289). Objective: The purpose of this clinical trial is to demonstrate the superiority of cytokine filtration in improving LTx outcome, based on its effects on oxygenation ratio, plasma levels of inflammatory markers, PGD incidence and severity, lung function, kidney function, survival, and quality of life compared with standard treatment with no cytokine filtration. Methods: This study is a Swedish national interventional randomized controlled trial involving 116 patients. Its primary objective is to investigate the potential benefits of cytokine filtration when used in conjunction with LTx. Specifically, this study aims to determine whether the application of cytokine filtration, administered for a duration of 12 hours within the initial 24 hours following a LTx procedure, can lead to improved patient outcomes. This study seeks to assess various aspects of patient recovery and overall health to ascertain the potential positive impact of this intervention on the posttransplantation course. Results: The process of patient recruitment for this study is scheduled to commence subsequent to a site initiation visit, which was slated to take place on August 28, 2023. The primary outcome measure that will be assessed in this research endeavor is the oxygenation ratio, a metric denoted as the highest PaO2/FiO2 ratio achieved by patients within a 72-hour timeframe following their LTx procedure. Conclusions: We propose that cytokine filtration could enhance the overall outcomes of LTx. Our hypothesis suggests potential improvements in LTx outcome and patient care. Trial Registration: ClinicalTrials.gov NCT05526950; https://www.clinicaltrials.gov/study/NCT05526950 International Registered Report Identifier (IRRID): PRR1-10.2196/52553
- 13 December 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12, e52553
Open AccessDesign and Rationale of Cytokine Filtration in Lung Transplantation (GLUSorb): Protocol for a Multicenter Clinical Randomized Controlled Trial
Background: Lung transplantation (LTx) is the only treatment option for end-stage lung disease. Despite improvements, primary graft dysfunction (PGD) remains the leading cause of early mortality and precipitates chronic lung allograft dysfunction, the main factor in late mortality after LTx. PGD develops within the first 72 hours and impairs the oxygenation capacity of the lung, measured as partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2). Increasing the PaO2/FiO2 ratio is thus critical and has an impact on survival. There is a general lack of effective treatments for PGD. When a transplanted lung is not accepted by the immune system in the recipient, a systemic inflammatory response starts where cytokines play a critical role in initiating, amplifying, and maintaining the inflammation leading to PGD. Cytokine filtration can remove these cytokines from the circulation, thus reducing inflammation. In a proof-of-concept preclinical porcine model of LTx, cytokine filtration improved oxygenation and decreased PGD. In a feasibility study, we successfully treated patients undergoing LTx with cytokine filtration (ClinicalTrials.gov; NCT05242289). Objective: The purpose of this clinical trial is to demonstrate the superiority of cytokine filtration in improving LTx outcome, based on its effects on oxygenation ratio, plasma levels of inflammatory markers, PGD incidence and severity, lung function, kidney function, survival, and quality of life compared with standard treatment with no cytokine filtration. Methods: This study is a Swedish national interventional randomized controlled trial involving 116 patients. Its primary objective is to investigate the potential benefits of cytokine filtration when used in conjunction with LTx. Specifically, this study aims to determine whether the application of cytokine filtration, administered for a duration of 12 hours within the initial 24 hours following a LTx procedure, can lead to improved patient outcomes. This study seeks to assess various aspects of patient recovery and overall health to ascertain the potential positive impact of this intervention on the posttransplantation course. Results: The process of patient recruitment for this study is scheduled to commence subsequent to a site initiation visit, which was slated to take place on August 28, 2023. The primary outcome measure that will be assessed in this research endeavor is the oxygenation ratio, a metric denoted as the highest PaO2/FiO2 ratio achieved by patients within a 72-hour timeframe following their LTx procedure. Conclusions: We propose that cytokine filtration could enhance the overall outcomes of LTx. Our hypothesis suggests potential improvements in LTx outcome and patient care. Trial Registration: ClinicalTrials.gov NCT05526950; https://www.clinicaltrials.gov/study/NCT05526950 International Registered Report Identifier (IRRID): PRR1-10.2196/52553
- Open Access
- 13 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Publisher Correction: Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
- 13 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessPublisher Correction: Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
- Open Access
- 29 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
There is a clinical need for conceptually new treatments that target the excessive activation of inflammatory pathways during systemic infection. Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses. Here we describe the development of a peptide-based compound for systemic use, sHVF18, expressing the evolutionarily conserved innate structural fold of natural TCPs. Using a combination of structure- and in silico-based design, nuclear magnetic resonance spectroscopy, biophysics, mass spectrometry, cellular, and in vivo studies, we here elucidate the structure, CD14 interactions, protease stability, transcriptome profiling, and therapeutic efficacy of sHVF18. The designed peptide displays a conformationally stabilized, protease resistant active innate fold and targets the LPS-binding groove of CD14. In vivo, it shows therapeutic efficacy in experimental models of endotoxin shock in mice and pigs and increases survival in mouse models of systemic polymicrobial infection. The results provide a drug class based on Nature´s own anti-infective principles.
- 29 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Open AccessTargeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
There is a clinical need for conceptually new treatments that target the excessive activation of inflammatory pathways during systemic infection. Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses. Here we describe the development of a peptide-based compound for systemic use, sHVF18, expressing the evolutionarily conserved innate structural fold of natural TCPs. Using a combination of structure- and in silico-based design, nuclear magnetic resonance spectroscopy, biophysics, mass spectrometry, cellular, and in vivo studies, we here elucidate the structure, CD14 interactions, protease stability, transcriptome profiling, and therapeutic efficacy of sHVF18. The designed peptide displays a conformationally stabilized, protease resistant active innate fold and targets the LPS-binding groove of CD14. In vivo, it shows therapeutic efficacy in experimental models of endotoxin shock in mice and pigs and increases survival in mouse models of systemic polymicrobial infection. The results provide a drug class based on Nature´s own anti-infective principles.
- Open Access
- 7 September 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Design and Rationale of Cytokine Filtration in Lung Transplantation (GLUSorb): Protocol for a Multicenter Clinical Randomized Controlled Trial (Preprint)
BACKGROUND Lung transplantation (LTx) is the only treatment option for end-stage lung disease. Despite improvements, primary graft dysfunction (PGD) remains the leading cause of early mortality and precipitates chronic lung allograft dysfunction, the main factor in late mortality after LTx. PGD develops within the first 72 hours and impairs the oxygenation capacity of the lung, measured as partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2). Increasing the PaO2/FiO2 ratio is thus critical and has an impact on survival. There is a general lack of effective treatments for PGD. When a transplanted lung is not accepted by the immune system in the recipient, a systemic inflammatory response starts where cytokines play a critical role in initiating, amplifying, and maintaining the inflammation leading to PGD. Cytokine filtration can remove these cytokines from the circulation, thus reducing inflammation. In a proof-of-concept preclinical porcine model of LTx, cytokine filtration improved oxygenation and decreased PGD. In a feasibility study, we successfully treated patients undergoing LTx with cytokine filtration (ClinicalTrials.gov; NCT05242289). OBJECTIVE The purpose of this clinical trial is to demonstrate the superiority of cytokine filtration in improving LTx outcome, based on its effects on oxygenation ratio, plasma levels of inflammatory markers, PGD incidence and severity, lung function, kidney function, survival, and quality of life compared with standard treatment with no cytokine filtration. METHODS This study is a Swedish national interventional randomized controlled trial involving 116 patients. Its primary objective is to investigate the potential benefits of cytokine filtration when used in conjunction with LTx. Specifically, this study aims to determine whether the application of cytokine filtration, administered for a duration of 12 hours within the initial 24 hours following a LTx procedure, can lead to improved patient outcomes. This study seeks to assess various aspects of patient recovery and overall health to ascertain the potential positive impact of this intervention on the posttransplantation course. RESULTS The process of patient recruitment for this study is scheduled to commence subsequent to a site initiation visit, which was slated to take place on August 28, 2023. The primary outcome measure that will be assessed in this research endeavor is the oxygenation ratio, a metric denoted as the highest PaO2/FiO2 ratio achieved by patients within a 72-hour timeframe following their LTx procedure. CONCLUSIONS We propose that cytokine filtration could enhance the overall outcomes of LTx. Our hypothesis suggests potential improvements in LTx outcome and patient care. CLINICALTRIAL ClinicalTrials.gov NCT05526950; https://www.clinicaltrials.gov/study/NCT05526950 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/52553
- 7 September 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDesign and Rationale of Cytokine Filtration in Lung Transplantation (GLUSorb): Protocol for a Multicenter Clinical Randomized Controlled Trial (Preprint)
BACKGROUND Lung transplantation (LTx) is the only treatment option for end-stage lung disease. Despite improvements, primary graft dysfunction (PGD) remains the leading cause of early mortality and precipitates chronic lung allograft dysfunction, the main factor in late mortality after LTx. PGD develops within the first 72 hours and impairs the oxygenation capacity of the lung, measured as partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2). Increasing the PaO2/FiO2 ratio is thus critical and has an impact on survival. There is a general lack of effective treatments for PGD. When a transplanted lung is not accepted by the immune system in the recipient, a systemic inflammatory response starts where cytokines play a critical role in initiating, amplifying, and maintaining the inflammation leading to PGD. Cytokine filtration can remove these cytokines from the circulation, thus reducing inflammation. In a proof-of-concept preclinical porcine model of LTx, cytokine filtration improved oxygenation and decreased PGD. In a feasibility study, we successfully treated patients undergoing LTx with cytokine filtration (ClinicalTrials.gov; NCT05242289). OBJECTIVE The purpose of this clinical trial is to demonstrate the superiority of cytokine filtration in improving LTx outcome, based on its effects on oxygenation ratio, plasma levels of inflammatory markers, PGD incidence and severity, lung function, kidney function, survival, and quality of life compared with standard treatment with no cytokine filtration. METHODS This study is a Swedish national interventional randomized controlled trial involving 116 patients. Its primary objective is to investigate the potential benefits of cytokine filtration when used in conjunction with LTx. Specifically, this study aims to determine whether the application of cytokine filtration, administered for a duration of 12 hours within the initial 24 hours following a LTx procedure, can lead to improved patient outcomes. This study seeks to assess various aspects of patient recovery and overall health to ascertain the potential positive impact of this intervention on the posttransplantation course. RESULTS The process of patient recruitment for this study is scheduled to commence subsequent to a site initiation visit, which was slated to take place on August 28, 2023. The primary outcome measure that will be assessed in this research endeavor is the oxygenation ratio, a metric denoted as the highest PaO2/FiO2 ratio achieved by patients within a 72-hour timeframe following their LTx procedure. CONCLUSIONS We propose that cytokine filtration could enhance the overall outcomes of LTx. Our hypothesis suggests potential improvements in LTx outcome and patient care. CLINICALTRIAL ClinicalTrials.gov NCT05526950; https://www.clinicaltrials.gov/study/NCT05526950 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/52553
- Open Access
- 20 June 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (10) , 1358-1362
Nothing but NETs: Cytokine adsorption correlates with lower circulating nucleosomes and is associated with decreased primary graft dysfunction
- 20 June 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (10) , 1358-1362
Open AccessNothing but NETs: Cytokine adsorption correlates with lower circulating nucleosomes and is associated with decreased primary graft dysfunction
- Open Access
- 28 November 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (1) , 691-698
New insight: Particle Flow Rate from the Airways as an Indicator of Cardiac Failure in the Intensive Care Unit
Aims: Exhaled breath particles have been explored for diagnosing different lung diseases. We recently showed in an experimental model that different cardiac output results in different particle flow rate (PFR) from the airways. Given the well-known close relationship between impaired cardiac function and respiratory failure, we hypothesized that PFR in exhaled air can be used to detect cardiac failure. Methods: PFR was analysed using a customized PExA device. Particles in the range of 0.41–4.55 μm were measured. The included patients (n = 20) underwent cardiac surgery and received mechanical ventilation as a part of routine post-operative care. Ten patients with clinical signs of pronounced post-operative haemodynamic instability and need for inotrope or mechanical support had been selected to the cardiac failure group. The control group consisted of 10 patients without signs of cardiac failure. Results: The patients in cardiac failure group required inotropic support in the form of dobutamine (9/10), epinephrine (2/10), or levosimendan (4/10) or use of an intra-aortic balloon pump (4/10). There was no use of inotropes or mechanical support devices among the controls. All patients in the cardiac failure group had pre-operative left ventricular ejection fraction ≤40% compared with the control group, whose pre-operative ejection fraction was ≥50%, P < 0.001. Patients with cardiac failure had significantly longer median total time in mechanical ventilation compared with the patients in the control group: 53.5 h (IQR 6.8–116101.0 h) and 4.5 h (IQR 4.0–5.5 h), respectively, P < 0.001, and the median length of stay in the ICU, 165 h (IQR 28–192 h) and 22 h (IQR 20–23.5 h), respectively, P = 0.007. Median PFR in patients with cardiac failure was higher than PFR in those with normal cardiac function: 80.9 particles/min (interquartile range (IQR) 25.8–336.6 particles/min), vs. 15.3 particles/min (IQR 8.1–17.7 particles/min), respectively, P < 0.001. Median particle mass was 8.95 ng (IQR 1.68–41.73 ng) in the cardiac failure group and 0.75 ng (IQR 0.18–1.45 ng) in the control group, P = 0.002. Conclusions: Patients with post-operative cardiac failure following cardiac surgery exhibited an increase in exhaled particle mass and PFR compared with the control group, indicating a significant difference between those two groups. The increase in particle mass and PFR in the absence of respiratory pathologies may indicate cardiac failure. In comparison with controls, impaired cardiac function was also associated with different composition of the particles regarding their size distribution.
- 28 November 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (1) , 691-698
Open AccessNew insight: Particle Flow Rate from the Airways as an Indicator of Cardiac Failure in the Intensive Care Unit
Aims: Exhaled breath particles have been explored for diagnosing different lung diseases. We recently showed in an experimental model that different cardiac output results in different particle flow rate (PFR) from the airways. Given the well-known close relationship between impaired cardiac function and respiratory failure, we hypothesized that PFR in exhaled air can be used to detect cardiac failure. Methods: PFR was analysed using a customized PExA device. Particles in the range of 0.41–4.55 μm were measured. The included patients (n = 20) underwent cardiac surgery and received mechanical ventilation as a part of routine post-operative care. Ten patients with clinical signs of pronounced post-operative haemodynamic instability and need for inotrope or mechanical support had been selected to the cardiac failure group. The control group consisted of 10 patients without signs of cardiac failure. Results: The patients in cardiac failure group required inotropic support in the form of dobutamine (9/10), epinephrine (2/10), or levosimendan (4/10) or use of an intra-aortic balloon pump (4/10). There was no use of inotropes or mechanical support devices among the controls. All patients in the cardiac failure group had pre-operative left ventricular ejection fraction ≤40% compared with the control group, whose pre-operative ejection fraction was ≥50%, P < 0.001. Patients with cardiac failure had significantly longer median total time in mechanical ventilation compared with the patients in the control group: 53.5 h (IQR 6.8–116101.0 h) and 4.5 h (IQR 4.0–5.5 h), respectively, P < 0.001, and the median length of stay in the ICU, 165 h (IQR 28–192 h) and 22 h (IQR 20–23.5 h), respectively, P = 0.007. Median PFR in patients with cardiac failure was higher than PFR in those with normal cardiac function: 80.9 particles/min (interquartile range (IQR) 25.8–336.6 particles/min), vs. 15.3 particles/min (IQR 8.1–17.7 particles/min), respectively, P < 0.001. Median particle mass was 8.95 ng (IQR 1.68–41.73 ng) in the cardiac failure group and 0.75 ng (IQR 0.18–1.45 ng) in the control group, P = 0.002. Conclusions: Patients with post-operative cardiac failure following cardiac surgery exhibited an increase in exhaled particle mass and PFR compared with the control group, indicating a significant difference between those two groups. The increase in particle mass and PFR in the absence of respiratory pathologies may indicate cardiac failure. In comparison with controls, impaired cardiac function was also associated with different composition of the particles regarding their size distribution.